Bio-Path Holdings to Announce First Quarter 2022 Financial Results on May 17, 2022

Rhea-AI Summary

Bio-Path Holdings (NASDAQ: BPTH) will hold a conference call on May 17, 2022, at 8:30 a.m. ET to discuss its Q1 financial results for the period ending March 31, 2022. The call will offer a business overview and can be accessed by phone or via a live audio webcast on the company's website. Bio-Path is advancing its proprietary DNAbilize^® technology, with lead candidate prexigebersen in a Phase 2 study for blood cancers and plans for Phase 1 studies of BP1001-A in solid tumors. The company aims to file an IND for BP1003 in 2022.

Positive

• Ongoing clinical studies for lead candidate prexigebersen targeting blood cancers.
• Plans to commence Phase 1 studies for BP1001-A in solid tumors in 2022.
• FDA clearance for BP1001-A enhances product pipeline.
• Upcoming IND filing for BP1003 expected in 2022.

Negative

• None.

HOUSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize^® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Tuesday, May 17, 2022 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2022 and to provide a business overview.

To access the live conference call, please call (844) 815-4963 (domestic) or (210) 229-8838 (international) at least five minutes prior to the start time and refer to conference ID 9488426. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company developing DNAbilize^®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and BP1001-A, a drug product modification of prexigebersen, has been cleared by the FDA and Phase 1 studies in solid tumors will commence in 2022. The Company’s second product BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. In addition, an IND is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3, in 2022.

For more information, please visit the Company's website at http://www.biopathholdings.com.

Contact Information:

Investors

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com

Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369

FAQ

When will Bio-Path Holdings report its Q1 2022 financial results?

Bio-Path Holdings will report its Q1 2022 financial results on May 17, 2022.

How can I listen to the Bio-Path Holdings conference call?

You can listen to the conference call by calling (844) 815-4963 (domestic) or (210) 229-8838 (international) or via the audio webcast on their website.

What is the lead product of Bio-Path Holdings?

The lead product of Bio-Path Holdings is prexigebersen (BP1001), which targets the Grb2 protein.

What new studies are planned for Bio-Path Holdings' drugs?

Bio-Path Holdings plans to commence Phase 1 studies for BP1001-A in 2022 and to file an IND for BP1003.